{"gene":"SMN2","run_date":"2026-06-10T07:46:36","timeline":{"discoveries":[{"year":1999,"finding":"A single C-to-T transition at position +6 in exon 7 is the critical difference between SMN1 and SMN2; this change causes the majority of SMN2 transcripts to skip exon 7, producing a shorter isoform, by disrupting an exonic splice enhancer activity.","method":"Complete genomic sequencing and comparison of SMN1 and SMN2 clones; splicing assays demonstrating differential exon 7 inclusion","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct sequencing plus functional splicing assays in the same study; independently replicated across multiple subsequent labs","pmids":["10369862"],"is_preprint":false},{"year":2000,"finding":"Htra2-beta1, an SR-like splicing factor, promotes inclusion of SMN exon 7 by binding an AG-rich exonic splicing enhancer in SMN2 exon 7, thereby restoring full-length SMN2 expression.","method":"In vivo splicing assays with Htra2-beta1 overexpression in human and mouse cells carrying an SMN2 minigene; RNA-binding assays demonstrating direct interaction with the ESE","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — overexpression and RNA-binding assays, replicated in multiple cell systems and confirmed by subsequent studies","pmids":["10931943"],"is_preprint":false},{"year":2000,"finding":"SMN2 transgene expression in Smn-null mice rescues embryonic lethality; one or two transgene copies produce severe SMA-like motor neuron loss, while eight copies rescue the phenotype, demonstrating that phenotypic severity is modulated by the level of SMN produced from SMN2.","method":"Transgenic mouse generation; crossing onto Smn-/- background; histological and survival analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue experiment in vivo with dose-response, foundational animal model study widely replicated","pmids":["10655541"],"is_preprint":false},{"year":1999,"finding":"The SMN1 and SMN2 gene promoters are nearly identical (~750 bp 5'-flanking region drives expression), with only a ~2-fold difference in reporter activity, ruling out promoter differences as the explanation for why SMN1 but not SMN2 is the disease-determining gene.","method":"Reporter construct transfection assays in motor neuron cell line using 750-bp 5'-flanking fragments from each gene","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct reporter assay with both promoters tested in parallel, single lab but multiple constructs","pmids":["10366716"],"is_preprint":false},{"year":2003,"finding":"The C-to-T transition in SMN2 exon 7 creates an exonic splicing silencer (ESS) that functions as a binding site for hnRNP A1, which represses SMN2 exon 7 splicing; RNAi knockdown of hnRNP A1 in cells promotes efficient SMN2 exon 7 inclusion.","method":"Mutagenesis of exon 7; RNA-protein interaction assays; siRNA knockdown of hnRNP A1 in living cells with splicing readout","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis, RNA-protein binding, and functional RNAi in cells; confirmed by multiple independent laboratories","pmids":["12833158"],"is_preprint":false},{"year":2005,"finding":"The C-to-T transition in SMN2 exon 7 results in loss of an SF2/ASF-dependent exonic splicing enhancer (ESE); hnRNP A/B proteins antagonize SF2/ASF-dependent ESE activity and promote exon 7 skipping independently of the C-to-T transition, representing a mechanism common to both SMN1 and SMN2.","method":"Mutagenesis, RNA interference, overexpression of splicing factors, RNA splicing assays, and RNA-protein interaction experiments","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (mutagenesis, RNAi, OE, binding assays) in a single study","pmids":["16385450"],"is_preprint":false},{"year":2005,"finding":"SMNDelta7 (the major SMN2 product lacking exon 7) associates with full-length SMN protein, and this association stabilizes SMNDelta7 and increases oligomeric SMN, ameliorating the SMA phenotype in transgenic mice.","method":"Transgenic mouse generation (SMNDelta7 crossed onto severe SMA background); survival analysis; co-immunoprecipitation/association assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic rescue plus molecular association assays; widely cited and built upon","pmids":["15703193"],"is_preprint":false},{"year":2007,"finding":"hnRNP A1 specifically binds SMN2 exon 7 (but not SMN1) and represses its splicing via the ESS mechanism; ASF/SF2 depletion does not affect SMN1/2 splicing, supporting the ESS-not-ESE model as primary mechanism.","method":"hnRNP A1 depletion by two independent methods; RNA-protein interaction assays; splicing assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent depletion methods plus binding assays, multiple orthogonal approaches","pmids":["17884807"],"is_preprint":false},{"year":2008,"finding":"Two tandem hnRNP A1/A2 motifs in the intron 7 intronic splicing silencer (ISS-N1) repress SMN2 exon 7 inclusion; antisense oligonucleotides (ASOs) blocking these motifs promote very efficient exon 7 inclusion in transgenic mice in vivo.","method":"ASO tiling screen; mutagenesis; splicing assays; RNA-affinity chromatography; protein overexpression; in vivo ASO delivery in transgenic mice","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis, RNA-affinity chromatography, in vitro and in vivo validation with multiple orthogonal methods","pmids":["18371932"],"is_preprint":false},{"year":2008,"finding":"Sam68 binds to the C-to-T transition-created binding site in SMN2 exon 7 (confirmed by RNA pull-down and UV-crosslink), triggers SMN2 exon 7 skipping, and dominant-negative Sam68 mutants that block hnRNP A1 recruitment enhance exon 7 inclusion and rescue SMN protein in SMA patient fibroblasts.","method":"RNA pull-down; UV crosslink; in vivo splicing assays; mutagenesis of Sam68 RNA-binding domain; retroviral dominant-negative mutant expression","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — RNA-protein binding, mutagenesis, and functional rescue in patient cells, multiple orthogonal methods","pmids":["20186123"],"is_preprint":false},{"year":2008,"finding":"hnRNP Q isoforms differentially regulate SMN2 exon 7 splicing: the major isoform Q1 directly binds SMN exon 7 near position +6 and promotes exon 7 inclusion, while minor isoforms Q2/Q3 antagonize Q1 and induce exon 7 exclusion.","method":"Affinity chromatography; overexpression and knockdown of hnRNP Q isoforms; splicing assays in HeLa cells and testis of SMN2 transgenic mice","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — affinity chromatography plus functional assays in cells and tissue, single lab","pmids":["18794368"],"is_preprint":false},{"year":2009,"finding":"The C-to-T transition in SMN2 exon 7 reduces U2AF65 crosslinking and U2 snRNP association at the 3' splice site of intron 6 compared to SMN1, suggesting that differential U2 snRNP recruitment is a control point in SMN2 exon 7 splicing regulation.","method":"UV crosslinking of U2AF65; native gel electrophoresis of U2 snRNP assembly on SMN1 vs SMN2 RNAs; competition assays in HeLa nuclear extract","journal":"RNA (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution with nuclear extract, multiple assays, single lab","pmids":["19244360"],"is_preprint":false},{"year":2010,"finding":"SMN protein abundance positively feeds back on SMN2 exon 7 splicing: reduced SMN protein lowers cellular snRNA levels, which in turn decreases SMN2 exon 7 inclusion, creating a self-amplifying feedback loop that exacerbates SMN deficiency.","method":"SMN depletion in cells; measurement of snRNA levels; SMN2 splicing assays; manipulation of individual snRNP levels with functional readout","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell-based experiments with depletion and snRNP manipulation, single lab","pmids":["20884664"],"is_preprint":false},{"year":2010,"finding":"Selective SMN depletion in motor neuronal progenitors (but not abolition) is sufficient to cause an SMA-like phenotype with neuromuscular junction defects, motor neuron degeneration, and muscle atrophy in model mice expressing human SMN2, establishing a cell-autonomous role for SMN in motor neurons.","method":"Conditional SMN knockdown in motor neuronal progenitors using Cre-mediated approach in SMN2-expressing mice; electrophysiology; histology; NMJ analysis","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic knockdown with multiple phenotypic readouts including electrophysiology and histology","pmids":["20826664"],"is_preprint":false},{"year":2010,"finding":"Intracerebroventricular delivery of a 2'-MOE ASO targeting the ISS-N1 element in SMN2 intron 7 produces robust, long-lasting SMN2 exon 7 inclusion in spinal cord motor neurons at both mRNA and protein levels, and a single neonatal injection rescues tail and ear necrosis in SMA mice.","method":"Micro-osmotic pump ICV infusion; quantitative RT-PCR and immunoblot of spinal cord; neonatal ICV injection in SMA mice with phenotype rescue readout","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct CNS delivery with mRNA, protein, and functional phenotype rescue readouts, multiple experimental arms","pmids":["20624852"],"is_preprint":false},{"year":2009,"finding":"SMN(A111G), an allele competent for snRNP assembly, rescues SMA mice only when combined with SMN from SMN2, indicating that SMN(A111G) and SMN2-derived SMN undergo intragenic complementation in heteromeric complexes with higher snRNP assembly activity; correction of SMA correlates directly with snRNP assembly activity in spinal cord.","method":"Transgenic rescue experiments; snRNP assembly assays; snRNA level measurement in spinal cord of rescued vs unrescued mice","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis combined with biochemical snRNP assembly assays, multiple animal genotypes","pmids":["19329542"],"is_preprint":false},{"year":2014,"finding":"SAM68 binds SMN2 pre-mRNA and favors recruitment of the splicing repressor hnRNP A1 while interfering with U2AF65 binding at the 3' splice site of exon 7; genetic knockout of SAM68 promotes SMN2 exon 7 inclusion in SMA mice and partially rescues body weight, viability, and motor neuron/muscle defects.","method":"SAM68 knockout in SMA mouse model; SMN2 splicing assay; molecular mechanism by RNA-binding and spliceosome factor recruitment analysis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in disease model with mechanistic analysis of splicing factor recruitment, multiple phenotypic readouts","pmids":["26438828"],"is_preprint":false},{"year":2014,"finding":"hnRNP G binds to an SMN2 exon 7-derived RNA via its RRM domain interacting with a 5'-AAN-3' motif (specifically recognizing two consecutive adenines), and is recruited to a polyA tract upstream of the Tra2-beta1 binding site; this interaction, together with the RGG box, is required for hnRNP G to activate exon 7 inclusion as part of a Tra2-beta1/hnRNP G/SRSF9 trimeric complex.","method":"NMR structure of hnRNP G RRM bound to SMN2-derived RNA; mutagenesis of RRM and binding sites; splicing assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure with mutagenesis validation and functional splicing assays in same study","pmids":["24692659"],"is_preprint":false},{"year":2014,"finding":"hnRNP M binds an enhancer on SMN2 exon 7 (overlapping the Tra2-beta1 binding site) and promotes exon 7 inclusion by recruiting U2AF65 to the flanking intron; knockdown promotes exon 7 skipping and overexpression promotes inclusion in SMA patient cells.","method":"Knockdown and overexpression of hnRNP M; RNA-binding assays; U2AF65 recruitment assay; splicing assays in SMA patient cells","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA binding plus functional splicing assays with KD and OE, single lab","pmids":["24533984"],"is_preprint":false},{"year":2014,"finding":"PSF (polypyrimidine tract-binding protein-associated splicing factor) binds the GAAGGA enhancer in SMN2 exon 7 and promotes exon 7 inclusion; mutation of this enhancer abolishes PSF's effect; PSF and Tra2-beta1 target partially overlapping sequences in exon 7.","method":"Overexpression and knockdown of PSF; mutagenesis of GAAGGA enhancer; RNA-protein interaction assays; splicing assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA binding, mutagenesis, KD and OE, single lab","pmids":["24632473"],"is_preprint":false},{"year":2015,"finding":"Small-molecule SMN2 splicing modifiers stabilize the transient double-stranded RNA structure formed between the SMN2 pre-mRNA 5' splice site and U1 snRNP, increasing U1 snRNP binding affinity in a sequence-selective manner distinct from constitutive splicing recognition.","method":"Biochemical U1 snRNP binding assays; RNA structural analysis; in vitro and in vivo splicing assays; survival studies in severe SMA mouse model","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mechanistic biochemical reconstitution of U1 snRNP binding plus structural RNA analysis and in vivo rescue, multiple orthogonal methods","pmids":["26030728"],"is_preprint":false},{"year":2017,"finding":"The A-44G transition in SMN2 intron 6 improves exon 7 splicing by markedly decreasing binding of the RNA-binding protein HuR (which acts as a splicing repressor at the -44 region); identified by RNA-affinity chromatography and mass spectrometry combined with systematic mutagenesis.","method":"Minigene systematic mutagenesis; RNA-affinity chromatography; mass spectrometry identification of HuR; functional splicing assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — RNA affinity chromatography/MS identification plus mutagenesis and functional splicing validation","pmids":["28460014"],"is_preprint":false},{"year":2017,"finding":"SMN2 splicing modifier small molecules (risdiplam class) directly bind to two distinct sites on the SMN2 pre-mRNA, stabilizing a ribonucleoprotein (RNP) complex that confers gene selectivity, rather than targeting the general splicing machinery.","method":"RNA splicing assays; transcription assays; protein chemistry; combination of RNA and protein binding techniques demonstrating direct pre-mRNA binding","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct binding to pre-mRNA shown by multiple biochemical/chemical methods, single lab but orthogonal approaches","pmids":["29133793"],"is_preprint":false},{"year":2018,"finding":"SMN-C2 and SMN-C3 (risdiplam analogs) directly bind the AGGAAG motif on SMN2 exon 7 pre-mRNA and promote a conformational change in unpaired nucleotides at the intron 6/exon 7 junction, creating a new binding surface that recruits FUBP1 and KHSRP to enhance SMN2 splicing.","method":"Chemical proteomics; SHAPE/structure probing of SMN2 pre-mRNA in vitro and in-cell; identification of recruited splicing factors FUBP1 and KHSRP","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct RNA binding mapping, RNA structural probing, and factor recruitment identification with multiple orthogonal methods","pmids":["29712837"],"is_preprint":false},{"year":2018,"finding":"The stem-loop RNA structure TSL2 (overlapping the 5' splice site of SMN2 exon 7) is a drugable target; the small molecule PK4C9 binds pentaloop conformations of TSL2 and promotes a shift to triloop conformations that enhance exon 7 splicing, rescuing downstream molecular alterations in SMA cells.","method":"High-resolution NMR with molecular modelling of PK4C9-TSL2 complex; SMN2 splicing assays; SMA cell molecular rescue readouts","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure of small molecule-RNA complex combined with functional splicing rescue","pmids":["29795225"],"is_preprint":false},{"year":2003,"finding":"Valproic acid increases full-length SMN2 mRNA and protein 2- to 4-fold in SMA patient fibroblasts, likely through elevation of Htra2-beta1 (which facilitates SMN2 exon 7 correct splicing) as well as through SMN gene transcription activation.","method":"Treatment of SMA patient fibroblast cultures with VPA; quantitative RT-PCR of SMN2 transcripts; western blot; immunofluorescence of gems; VPA treatment of rat hippocampal brain slices","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based and organotypic experiments with mRNA and protein readouts, single lab","pmids":["12915451"],"is_preprint":false},{"year":2012,"finding":"Hypoxia increases hnRNP A1 and Sam68 levels in cells and promotes SMN2 exon 7 skipping; this hypoxia-induced skipping requires the SMN2 C>T mutation and is mediated through hnRNP A1 binding sites; hyperoxia treatment in SMA mice increases SMN2 exon 7 inclusion in skeletal muscle and improves motor function.","method":"Cell culture hypoxia treatment; SMN2 minigene splicing assays; mutation of hnRNP A1 binding sites; hyperoxia treatment in SMA mice with motor function readout","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — minigene mutagenesis, cell-based and in vivo experiments, single lab","pmids":["22763238"],"is_preprint":false},{"year":2020,"finding":"ZPR1 binds RNA polymerase II, interacts with the SMN locus in vivo, and upregulates SMN2 expression; ZPR1 overexpression in SMA mice increases systemic SMN levels, rescues motor function, and reduces neurodegeneration; ZPR1 also elevates senataxin levels, reduces R-loop accumulation, and rescues DNA damage in SMA.","method":"ZPR1-RNA Pol II binding assay; chromatin immunoprecipitation at SMN locus; ZPR1 overexpression in SMA mice; SMN level quantification; R-loop and DNA damage assays in patient cells and mice","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple molecular and in vivo assays, single lab","pmids":["31828288"],"is_preprint":false},{"year":2014,"finding":"Exon-specific U1 snRNAs (ExSpe U1s) complementary to intronic sequences downstream of the SMN2 exon 7 5' splice site promote exon 7 inclusion and stabilize the SMN pre-mRNA intermediate, resulting in higher SMN mRNA levels than antisense oligonucleotides targeting the same intronic region; AAV-delivered ExSpe U1 increases exon 7 inclusion in multiple tissues of SMN2 transgenic mice.","method":"Integrated ExSpe U1 expression; pre-mRNA stability assay; comparison with ASO; AAV delivery in SMN2 transgenic mice with tissue-level splicing analysis","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cellular models plus in vivo AAV delivery, single lab","pmids":["25557785"],"is_preprint":false}],"current_model":"SMN2 produces predominantly exon-7-skipped, unstable SMNDelta7 protein due to a single C-to-T transition at exon 7 position +6, which simultaneously destroys an SF2/ASF-dependent exonic splicing enhancer and creates an hnRNP A1-binding exonic splicing silencer; additional repression is exerted by hnRNP A1/A2 motifs in the intron 7 ISS-N1 element, by Sam68 (which recruits hnRNP A1 and blocks U2AF65), by HuR binding at intron 6 position -44, and by hypoxia-induced upregulation of hnRNP A1 and Sam68, while positive regulators including Htra2-beta1/SRSF10, hnRNP G, hnRNP M, PSF, hnRNP Q1, and ZPR1 act on exon 7 enhancers or at the transcriptional level to increase full-length SMN2 output; small-molecule splicing modifiers (risdiplam, branaplam class) directly bind specific RNA structures in the SMN2 pre-mRNA (AGGAAG motif on exon 7 and/or TSL2 stem-loop at the 5' splice site) to stabilize U1 snRNP recognition and recruit additional splicing activators (FUBP1, KHSRP), thereby shifting splicing toward full-length SMN protein, and SMN2 copy number inversely correlates with SMA severity because more copies produce cumulatively more full-length SMN protein, which itself feeds back to maintain snRNP levels required for efficient exon 7 splicing."},"narrative":{"mechanistic_narrative":"SMN2 is a near-identical paralog of SMN1 whose disease relevance in spinal muscular atrophy derives from a single C-to-T transition at exon 7 position +6 that causes most transcripts to skip exon 7 and produce an unstable, truncated SMNDelta7 isoform, while a minority of transcripts retain exon 7 to yield functional full-length SMN [PMID:10369862]. The transition acts at the RNA level rather than through the essentially identical promoters [PMID:10366716]: it simultaneously abolishes an SF2/ASF-dependent exonic splicing enhancer [PMID:16385450] and creates an exonic splicing silencer that recruits the repressor hnRNP A1, whose depletion restores exon 7 inclusion [PMID:12833158, PMID:17884807]. Additional repression operates through tandem hnRNP A1/A2 motifs in the intron 7 ISS-N1 element [PMID:18371932], through Sam68/SAM68, which recruits hnRNP A1 and blocks U2AF65 at the exon 7 3' splice site [PMID:20186123, PMID:26438828], and through HuR binding near intron 6 position -44 [PMID:28460014], with reduced U2AF65 and U2 snRNP recruitment a key downstream consequence of the transition [PMID:19244360]. Opposing these silencers, Htra2-beta1, hnRNP G and hnRNP M act on exon 7 enhancers to drive inclusion [PMID:10931943, PMID:24692659, PMID:24533984], while transcriptional activators such as ZPR1 raise overall SMN2 output [PMID:31828288]. SMN2 copy number determines SMA severity because cumulative full-length SMN restores snRNP assembly, and SMN itself feeds back on snRNA levels to maintain efficient exon 7 splicing [PMID:10655541, PMID:20884664, PMID:19329542]; SMN function in motor neurons is cell-autonomous [PMID:20826664]. These mechanisms define the therapeutic strategy of redirecting SMN2 splicing toward full-length protein, achieved by ISS-N1-targeting antisense oligonucleotides [PMID:18371932, PMID:20624852] and by small-molecule modifiers that bind defined RNA elements (the exon 7 AGGAAG motif and the 5' splice-site TSL2 stem-loop) to stabilize U1 snRNP recognition and recruit activators such as FUBP1 and KHSRP [PMID:26030728, PMID:29712837, PMID:29795225].","teleology":[{"year":1999,"claim":"Established why SMN1 and SMN2 differ functionally despite sequence identity, pinpointing a single exon 7 nucleotide change as the cause of exon 7 skipping.","evidence":"Complete genomic sequencing and splicing assays comparing SMN1/SMN2 clones","pmids":["10369862"],"confidence":"High","gaps":["The molecular identity of the disrupted enhancer/silencer factor was not resolved","Did not establish whether the effect was enhancer loss or silencer gain"]},{"year":1999,"claim":"Ruled out promoter/transcriptional differences as the explanation for SMN1-versus-SMN2 disease determination, focusing attention on post-transcriptional splicing.","evidence":"Parallel reporter assays of 750-bp 5'-flanking fragments in a motor neuron line","pmids":["10366716"],"confidence":"Medium","gaps":["Reporter context may not capture native chromatin regulation","Modest 2-fold difference not functionally tested in vivo"]},{"year":2000,"claim":"Demonstrated that SMN dosage from SMN2 directly sets phenotypic severity in vivo, validating SMN2 as the disease-modifying gene and copy-number determinant.","evidence":"SMN2 transgene copy-number titration on a Smn-null mouse background with survival/histology","pmids":["10655541"],"confidence":"High","gaps":["Did not resolve the splicing mechanism limiting full-length output","Mouse SMN2 expression may differ from human tissue distribution"]},{"year":2000,"claim":"Identified the first positive trans-acting regulator, showing exon 7 inclusion can be enhanced by an SR-like factor binding an exonic enhancer.","evidence":"Htra2-beta1 overexpression with SMN2 minigenes and RNA-binding assays","pmids":["10931943"],"confidence":"High","gaps":["Did not establish whether endogenous Htra2-beta1 is rate-limiting in motor neurons"]},{"year":2003,"claim":"Provided early pharmacological proof that small molecules can raise full-length SMN2 output, linking it to Htra2-beta1 and transcriptional activation.","evidence":"Valproic acid treatment of SMA fibroblasts and rat brain slices with mRNA/protein readouts","pmids":["12915451"],"confidence":"Medium","gaps":["Mechanism inferred, not directly demonstrated as causal","Magnitude of effect modest (2-4 fold)"]},{"year":2003,"claim":"Resolved the molecular consequence of the C-to-T change as creation of a silencer, identifying hnRNP A1 as the responsible repressor.","evidence":"Exon 7 mutagenesis, RNA-protein binding, and hnRNP A1 RNAi in cells","pmids":["12833158"],"confidence":"High","gaps":["Did not reconcile with concurrent enhancer-loss models","Did not address intronic repressor contributions"]},{"year":2005,"claim":"Defined a parallel enhancer-loss mechanism (SF2/ASF-dependent ESE) and an hnRNP A/B antagonism common to both genes, broadening the regulatory model.","evidence":"Mutagenesis, RNAi, overexpression, and RNA-protein binding assays","pmids":["16385450"],"confidence":"High","gaps":["Relative weight of ESE-loss versus ESS-gain left unsettled"]},{"year":2005,"claim":"Explained why residual SMNDelta7 is not entirely inert, showing it associates with and is stabilized by full-length SMN to partially ameliorate disease.","evidence":"SMNDelta7 transgenic crosses with survival and association assays","pmids":["15703193"],"confidence":"High","gaps":["Quantitative contribution of stabilized SMNDelta7 to function not defined"]},{"year":2007,"claim":"Reinforced the silencer-centric model by showing hnRNP A1 binds SMN2 but not SMN1 exon 7 and that ASF/SF2 depletion does not alter splicing.","evidence":"Two independent hnRNP A1 depletion methods plus binding and splicing assays","pmids":["17884807"],"confidence":"High","gaps":["Apparent conflict with ESE-loss model not fully reconciled"]},{"year":2008,"claim":"Identified the intron 7 ISS-N1 element and its tandem hnRNP A1/A2 motifs as a potent silencer, defining the highest-value antisense therapeutic target.","evidence":"ASO tiling, mutagenesis, RNA-affinity chromatography, and in vivo ASO delivery in mice","pmids":["18371932"],"confidence":"High","gaps":["Long-term and clinical efficacy not addressed in this study"]},{"year":2008,"claim":"Implicated Sam68 as a repressor acting at the C-to-T site and showed dominant-negative Sam68 rescues SMN in patient cells.","evidence":"RNA pull-down, UV-crosslink, mutagenesis, and dominant-negative expression","pmids":["20186123"],"confidence":"High","gaps":["In vivo relevance not yet tested at this stage"]},{"year":2008,"claim":"Added isoform-specific complexity by showing hnRNP Q1 promotes while Q2/Q3 antagonize exon 7 inclusion.","evidence":"Affinity chromatography, overexpression/knockdown, splicing assays in cells and mouse tissue","pmids":["18794368"],"confidence":"Medium","gaps":["Single lab; physiological isoform balance in motor neurons unknown"]},{"year":2009,"claim":"Provided biochemical evidence that the C-to-T change weakens U2AF65 crosslinking and U2 snRNP recruitment, linking the silencer to early spliceosome assembly.","evidence":"UV crosslinking and native-gel U2 snRNP assembly in HeLa nuclear extract","pmids":["19244360"],"confidence":"Medium","gaps":["In vitro extract may not reflect motor neuron context"]},{"year":2009,"claim":"Showed that correction of SMA correlates directly with snRNP assembly activity and that SMN2-derived SMN complements via heteromeric complexes.","evidence":"Transgenic rescue with snRNP assembly and snRNA assays in spinal cord","pmids":["19329542"],"confidence":"High","gaps":["Whether snRNP assembly fully accounts for motor neuron pathology unresolved"]},{"year":2010,"claim":"Established a self-amplifying feedback loop in which low SMN reduces snRNA and further suppresses exon 7 inclusion, worsening deficiency.","evidence":"SMN depletion, snRNA measurement, and snRNP manipulation with splicing readout","pmids":["20884664"],"confidence":"Medium","gaps":["Single lab; quantitative contribution of the loop to disease progression unknown"]},{"year":2010,"claim":"Demonstrated a cell-autonomous requirement for SMN in motor neurons, defining the relevant cellular target of SMN2-derived protein.","evidence":"Conditional SMN knockdown in motor neuronal progenitors with electrophysiology and NMJ analysis","pmids":["20826664"],"confidence":"High","gaps":["Non-cell-autonomous contributions not excluded"]},{"year":2010,"claim":"Provided CNS proof-of-concept that ISS-N1 ASO delivery restores SMN in spinal motor neurons and rescues phenotype.","evidence":"ICV 2'-MOE ASO infusion and neonatal injection in SMA mice with mRNA/protein/phenotype readouts","pmids":["20624852"],"confidence":"High","gaps":["Durability and systemic distribution not fully characterized here"]},{"year":2014,"claim":"Mapped the structural basis and trimeric complex (Tra2-beta1/hnRNP G/SRSF9) by which hnRNP G activates exon 7 inclusion.","evidence":"NMR structure of hnRNP G RRM bound to SMN2 RNA with mutagenesis and splicing assays","pmids":["24692659"],"confidence":"High","gaps":["In vivo therapeutic relevance not tested"]},{"year":2014,"claim":"Identified hnRNP M as an enhancer-binding activator that recruits U2AF65 to promote exon 7 inclusion.","evidence":"Knockdown/overexpression, RNA-binding, and U2AF65 recruitment assays in patient cells","pmids":["24533984"],"confidence":"Medium","gaps":["Single lab; in vivo role unknown"]},{"year":2014,"claim":"Identified PSF as a GAAGGA-enhancer-binding activator overlapping the Tra2-beta1 target.","evidence":"Overexpression/knockdown, enhancer mutagenesis, and RNA-binding assays","pmids":["24632473"],"confidence":"Medium","gaps":["Single lab; physiological contribution unquantified"]},{"year":2014,"claim":"Confirmed Sam68's in vivo significance by showing genetic knockout enhances exon 7 inclusion and partially rescues SMA mice through impaired hnRNP A1 recruitment and U2AF65 displacement.","evidence":"SAM68 knockout in SMA mice with mechanistic splicing factor recruitment analysis","pmids":["26438828"],"confidence":"High","gaps":["Only partial rescue; off-target Sam68 functions not dissected"]},{"year":2014,"claim":"Demonstrated an alternative RNA-based therapeutic using exon-specific U1 snRNAs that outperform ASOs by stabilizing pre-mRNA intermediates.","evidence":"ExSpe U1 expression, pre-mRNA stability assays, and AAV delivery in SMN2 transgenic mice","pmids":["25557785"],"confidence":"Medium","gaps":["Single lab; clinical translatability not addressed"]},{"year":2015,"claim":"Revealed the core mechanism of small-molecule splicing modifiers: stabilizing the transient pre-mRNA/U1 snRNP duplex at the 5' splice site in a sequence-selective manner.","evidence":"Biochemical U1 snRNP binding, RNA structural analysis, and in vivo SMA mouse survival","pmids":["26030728"],"confidence":"High","gaps":["Full set of recruited factors not yet defined at this stage"]},{"year":2017,"claim":"Identified HuR as an intron 6 (-44) repressor whose displacement by the A-44G change improves splicing.","evidence":"Minigene mutagenesis, RNA-affinity chromatography/MS, and splicing assays","pmids":["28460014"],"confidence":"High","gaps":["Whether HuR can be therapeutically modulated not addressed"]},{"year":2017,"claim":"Showed risdiplam-class modifiers act by directly binding two distinct pre-mRNA sites and stabilizing a selective RNP rather than the general spliceosome.","evidence":"RNA/transcription/protein binding assays demonstrating direct pre-mRNA binding","pmids":["29133793"],"confidence":"High","gaps":["Identity of all recruited factors not fully enumerated here"]},{"year":2018,"claim":"Defined the molecular details of modifier action, mapping binding to the exon 7 AGGAAG motif and identifying FUBP1 and KHSRP as recruited activators.","evidence":"Chemical proteomics, in vitro/in-cell SHAPE probing, and factor identification","pmids":["29712837"],"confidence":"High","gaps":["Relative contributions of FUBP1 versus KHSRP not quantified"]},{"year":2018,"claim":"Established the TSL2 stem-loop at the 5' splice site as a druggable RNA conformational switch for enhancing exon 7 splicing.","evidence":"NMR/modelling of PK4C9-TSL2 complex with splicing rescue in SMA cells","pmids":["29795225"],"confidence":"High","gaps":["In vivo efficacy of this chemotype not demonstrated"]},{"year":2012,"claim":"Linked environmental hypoxia to splicing repression via induction of hnRNP A1 and Sam68, with hyperoxia improving SMN2 inclusion in vivo.","evidence":"Cell hypoxia, minigene mutagenesis of hnRNP A1 sites, and hyperoxia treatment in SMA mice","pmids":["22763238"],"confidence":"Medium","gaps":["Single lab; clinical relevance of oxygenation uncertain"]},{"year":2020,"claim":"Identified ZPR1 as a transcriptional/genome-stability regulator that raises SMN2 expression, rescues motor function, and reduces R-loop-associated DNA damage.","evidence":"RNA Pol II binding, ChIP at SMN locus, ZPR1 overexpression in SMA mice, and R-loop/DNA damage assays","pmids":["31828288"],"confidence":"Medium","gaps":["Single lab; therapeutic feasibility of ZPR1 modulation untested"]},{"year":null,"claim":"How the many overlapping enhancer/silencer factors are integrated and prioritized in human motor neurons, and which are rate-limiting therapeutic targets, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Quantitative hierarchy of trans-acting regulators in motor neurons unknown","Combinatorial logic linking splicing factor occupancy to exon 7 outcome undefined","Long-term durability of splice-redirecting therapies not established in this corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[4,8,9,17,21,23]}],"localization":[],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0,4,8,20]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,27]}],"complexes":["snRNP"],"partners":["SMN1","HNRNP A1","SAM68","HTRA2-BETA1","HNRNP G","U2AF65","FUBP1","KHSRP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16637","full_name":"Survival motor neuron protein","aliases":["Component of gems 1","Gemin-1"],"length_aa":294,"mass_kda":31.8,"function":"The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:18984161, PubMed:9845364). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core) (PubMed:18984161). In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP (PubMed:18984161). To assemble core snRNPs, the SMN complex accepts the trapped 5Sm proteins from CLNS1A forming an intermediate (PubMed:18984161). Within the SMN complex, SMN1 acts as a structural backbone and together with GEMIN2 it gathers the Sm complex subunits (PubMed:17178713, PubMed:21816274, PubMed:22101937). Binding of snRNA inside 5Sm ultimately triggers eviction of the SMN complex, thereby allowing binding of SNRPD3 and SNRPB to complete assembly of the core snRNP (PubMed:31799625). Ensures the correct splicing of U12 intron-containing genes that may be important for normal motor and proprioceptive neurons development (PubMed:23063131). Also required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination (PubMed:26700805). May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs)","subcellular_location":"Nucleus, gem; Nucleus, Cajal body; Cytoplasm; Cytoplasmic granule; Perikaryon; Cell projection, neuron projection; Cell projection, axon; Cytoplasm, myofibril, sarcomere, Z line","url":"https://www.uniprot.org/uniprotkb/Q16637/entry"},"depmap":{"release":"DepMap","has_data":false,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SMN2"},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SMN2","total_profiled":1310},"omim":[{"mim_id":"606722","title":"NEUROCALCIN, DELTA; NCALD","url":"https://www.omim.org/entry/606722"},{"mim_id":"604454","title":"WELANDER DISTAL MYOPATHY; WDM","url":"https://www.omim.org/entry/604454"},{"mim_id":"603901","title":"ZPR1 ZINC FINGER PROTEIN; ZPR1","url":"https://www.omim.org/entry/603901"},{"mim_id":"603518","title":"TIA1 CYTOTOXIC GRANULE-ASSOCIATED RNA-BINDING PROTEIN; TIA1","url":"https://www.omim.org/entry/603518"},{"mim_id":"602719","title":"TRANSFORMER 2 BETA HOMOLOG; TRA2B","url":"https://www.omim.org/entry/602719"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear bodies","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SMN2"},"hgnc":{"alias_symbol":["BCD541","SMNC","GEMIN1","TDRD16B"],"prev_symbol":[]},"alphafold":{"accession":"Q16637","domains":[{"cath_id":"2.30.30.140","chopping":"97-138","consensus_level":"high","plddt":94.6993,"start":97,"end":138}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16637","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16637-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16637-F1-predicted_aligned_error_v6.png","plddt_mean":66.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SMN2","jax_strain_url":"https://www.jax.org/strain/search?query=SMN2"},"sequence":{"accession":"Q16637","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16637.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16637/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16637"}},"corpus_meta":[{"pmid":"11791208","id":"PMC_11791208","title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.","date":"2001","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11791208","citation_count":795,"is_preprint":false},{"pmid":"10369862","id":"PMC_10369862","title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10369862","citation_count":787,"is_preprint":false},{"pmid":"10655541","id":"PMC_10655541","title":"The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10655541","citation_count":600,"is_preprint":false},{"pmid":"20624852","id":"PMC_20624852","title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.","date":"2010","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/20624852","citation_count":531,"is_preprint":false},{"pmid":"15703193","id":"PMC_15703193","title":"SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15703193","citation_count":517,"is_preprint":false},{"pmid":"18371932","id":"PMC_18371932","title":"Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice.","date":"2008","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18371932","citation_count":479,"is_preprint":false},{"pmid":"9199562","id":"PMC_9199562","title":"Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number.","date":"1997","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9199562","citation_count":452,"is_preprint":false},{"pmid":"12833158","id":"PMC_12833158","title":"A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12833158","citation_count":448,"is_preprint":false},{"pmid":"25104390","id":"PMC_25104390","title":"Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy.","date":"2014","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/25104390","citation_count":422,"is_preprint":false},{"pmid":"30044619","id":"PMC_30044619","title":"Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30044619","citation_count":408,"is_preprint":false},{"pmid":"33743238","id":"PMC_33743238","title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.","date":"2021","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33743238","citation_count":380,"is_preprint":false},{"pmid":"29433793","id":"PMC_29433793","title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases.","date":"2018","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/29433793","citation_count":350,"is_preprint":false},{"pmid":"26030728","id":"PMC_26030728","title":"SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice.","date":"2015","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/26030728","citation_count":347,"is_preprint":false},{"pmid":"12915451","id":"PMC_12915451","title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.","date":"2003","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12915451","citation_count":301,"is_preprint":false},{"pmid":"17355180","id":"PMC_17355180","title":"Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon.","date":"2007","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/17355180","citation_count":281,"is_preprint":false},{"pmid":"10931943","id":"PMC_10931943","title":"Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10931943","citation_count":274,"is_preprint":false},{"pmid":"11839954","id":"PMC_11839954","title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2.","date":"2002","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11839954","citation_count":270,"is_preprint":false},{"pmid":"16508748","id":"PMC_16508748","title":"Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number.","date":"2006","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16508748","citation_count":264,"is_preprint":false},{"pmid":"16385450","id":"PMC_16385450","title":"Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2.","date":"2005","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16385450","citation_count":249,"is_preprint":false},{"pmid":"11354640","id":"PMC_11354640","title":"SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens.","date":"2001","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11354640","citation_count":188,"is_preprint":false},{"pmid":"29133793","id":"PMC_29133793","title":"Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29133793","citation_count":166,"is_preprint":false},{"pmid":"17884807","id":"PMC_17884807","title":"hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17884807","citation_count":151,"is_preprint":false},{"pmid":"20826664","id":"PMC_20826664","title":"Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene.","date":"2010","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20826664","citation_count":131,"is_preprint":false},{"pmid":"20186123","id":"PMC_20186123","title":"The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20186123","citation_count":110,"is_preprint":false},{"pmid":"29712837","id":"PMC_29712837","title":"Mechanistic studies of a small-molecule modulator of SMN2 splicing.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29712837","citation_count":108,"is_preprint":false},{"pmid":"15470363","id":"PMC_15470363","title":"New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations.","date":"2004","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/15470363","citation_count":101,"is_preprint":false},{"pmid":"16724231","id":"PMC_16724231","title":"The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.","date":"2006","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16724231","citation_count":101,"is_preprint":false},{"pmid":"12242541","id":"PMC_12242541","title":"Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity.","date":"2002","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12242541","citation_count":100,"is_preprint":false},{"pmid":"18794368","id":"PMC_18794368","title":"The RNA binding protein hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2 (SMN2) gene.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18794368","citation_count":98,"is_preprint":false},{"pmid":"12815596","id":"PMC_12815596","title":"Determination of SMN1 and SMN2 copy number using TaqMan technology.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12815596","citation_count":95,"is_preprint":false},{"pmid":"9801871","id":"PMC_9801871","title":"Correlation of SMNt and SMNc gene copy number with age of onset and survival in spinal muscular atrophy.","date":"1998","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/9801871","citation_count":94,"is_preprint":false},{"pmid":"30407821","id":"PMC_30407821","title":"Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA).","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30407821","citation_count":94,"is_preprint":false},{"pmid":"15981080","id":"PMC_15981080","title":"SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings.","date":"2005","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15981080","citation_count":86,"is_preprint":false},{"pmid":"19329542","id":"PMC_19329542","title":"A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19329542","citation_count":83,"is_preprint":false},{"pmid":"28460014","id":"PMC_28460014","title":"A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28460014","citation_count":83,"is_preprint":false},{"pmid":"16226920","id":"PMC_16226920","title":"Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs.","date":"2005","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16226920","citation_count":83,"is_preprint":false},{"pmid":"17551501","id":"PMC_17551501","title":"Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing.","date":"2007","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17551501","citation_count":74,"is_preprint":false},{"pmid":"18205293","id":"PMC_18205293","title":"Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.","date":"2008","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18205293","citation_count":72,"is_preprint":false},{"pmid":"16931506","id":"PMC_16931506","title":"SMN1 gene, but not SMN2, is a risk factor for sporadic ALS.","date":"2006","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16931506","citation_count":71,"is_preprint":false},{"pmid":"20577007","id":"PMC_20577007","title":"The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor.","date":"2010","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20577007","citation_count":71,"is_preprint":false},{"pmid":"18941511","id":"PMC_18941511","title":"Development of a single vector system that enhances trans-splicing of SMN2 transcripts.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18941511","citation_count":71,"is_preprint":false},{"pmid":"10366716","id":"PMC_10366716","title":"Promoter analysis of the human centromeric and telomeric survival motor neuron genes (SMNC and SMNT).","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10366716","citation_count":70,"is_preprint":false},{"pmid":"30788592","id":"PMC_30788592","title":"Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype.","date":"2019","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30788592","citation_count":70,"is_preprint":false},{"pmid":"20884664","id":"PMC_20884664","title":"A feedback loop regulates splicing of the spinal muscular atrophy-modifying gene, SMN2.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20884664","citation_count":70,"is_preprint":false},{"pmid":"22187232","id":"PMC_22187232","title":"Homozygous SMN2 deletion is a major risk factor among twenty-five Korean sporadic amyotrophic lateral sclerosis patients.","date":"2012","source":"Yonsei medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/22187232","citation_count":70,"is_preprint":false},{"pmid":"20161659","id":"PMC_20161659","title":"Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy.","date":"2009","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20161659","citation_count":67,"is_preprint":false},{"pmid":"36669496","id":"PMC_36669496","title":"Comprehensive SMN1 and SMN2 profiling for spinal muscular atrophy analysis using long-read PacBio HiFi sequencing.","date":"2023","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36669496","citation_count":64,"is_preprint":false},{"pmid":"10205267","id":"PMC_10205267","title":"The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements.","date":"1999","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10205267","citation_count":64,"is_preprint":false},{"pmid":"23630626","id":"PMC_23630626","title":"Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23630626","citation_count":64,"is_preprint":false},{"pmid":"16580882","id":"PMC_16580882","title":"Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector.","date":"2006","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16580882","citation_count":62,"is_preprint":false},{"pmid":"34360669","id":"PMC_34360669","title":"Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34360669","citation_count":61,"is_preprint":false},{"pmid":"15832310","id":"PMC_15832310","title":"Quantitative analysis of SMN1 and SMN2 genes based on DHPLC: a highly efficient and reliable carrier-screening test.","date":"2005","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15832310","citation_count":57,"is_preprint":false},{"pmid":"10556301","id":"PMC_10556301","title":"Detection of the survival motor neuron (SMN) genes by FISH: further evidence for a role for SMN2 in the modulation of disease severity in SMA patients.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10556301","citation_count":57,"is_preprint":false},{"pmid":"29795225","id":"PMC_29795225","title":"Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29795225","citation_count":56,"is_preprint":false},{"pmid":"29598153","id":"PMC_29598153","title":"Seamless Genetic Conversion of SMN2 to SMN1 via CRISPR/Cpf1 and Single-Stranded Oligodeoxynucleotides in Spinal Muscular Atrophy Patient-Specific Induced Pluripotent Stem Cells.","date":"2018","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29598153","citation_count":54,"is_preprint":false},{"pmid":"31828288","id":"PMC_31828288","title":"ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.","date":"2020","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31828288","citation_count":53,"is_preprint":false},{"pmid":"26247043","id":"PMC_26247043","title":"SMN1 and SMN2 copy numbers in cell lines derived from patients with spinal muscular atrophy as measured by array digital PCR.","date":"2015","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26247043","citation_count":52,"is_preprint":false},{"pmid":"32144995","id":"PMC_32144995","title":"Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?","date":"2020","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32144995","citation_count":52,"is_preprint":false},{"pmid":"18842367","id":"PMC_18842367","title":"Combination of SMN2 copy number and NAIP deletion predicts disease severity in spinal muscular atrophy.","date":"2008","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/18842367","citation_count":51,"is_preprint":false},{"pmid":"25557785","id":"PMC_25557785","title":"Improvement of SMN2 pre-mRNA processing mediated by exon-specific U1 small nuclear RNA.","date":"2014","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25557785","citation_count":51,"is_preprint":false},{"pmid":"33324756","id":"PMC_33324756","title":"Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy.","date":"2020","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33324756","citation_count":50,"is_preprint":false},{"pmid":"24692659","id":"PMC_24692659","title":"Characterization of the RNA recognition mode of hnRNP G extends its role in SMN2 splicing regulation.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24692659","citation_count":46,"is_preprint":false},{"pmid":"12673282","id":"PMC_12673282","title":"Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1.","date":"2003","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/12673282","citation_count":42,"is_preprint":false},{"pmid":"15804053","id":"PMC_15804053","title":"Implication of fetal SMN2 expression in type I SMA pathogenesis: protection or pathological gain of function?","date":"2005","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15804053","citation_count":42,"is_preprint":false},{"pmid":"24359787","id":"PMC_24359787","title":"Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients.","date":"2013","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/24359787","citation_count":42,"is_preprint":false},{"pmid":"24014320","id":"PMC_24014320","title":"Pathological impact of SMN2 mis-splicing in adult SMA mice.","date":"2013","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24014320","citation_count":39,"is_preprint":false},{"pmid":"23352792","id":"PMC_23352792","title":"Molecular analysis of SMN1, SMN2, NAIP, GTF2H2, and H4F5 genes in 157 Chinese patients with spinal muscular atrophy.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23352792","citation_count":39,"is_preprint":false},{"pmid":"22029744","id":"PMC_22029744","title":"Decreasing disease severity in symptomatic, Smn(-/-);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN delivery.","date":"2012","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22029744","citation_count":39,"is_preprint":false},{"pmid":"37026480","id":"PMC_37026480","title":"Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/37026480","citation_count":38,"is_preprint":false},{"pmid":"21443782","id":"PMC_21443782","title":"Generation and Characterization of a genetic zebrafish model of SMA carrying the human SMN2 gene.","date":"2011","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/21443782","citation_count":38,"is_preprint":false},{"pmid":"24533984","id":"PMC_24533984","title":"hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24533984","citation_count":37,"is_preprint":false},{"pmid":"31811660","id":"PMC_31811660","title":"Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.","date":"2020","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31811660","citation_count":35,"is_preprint":false},{"pmid":"15162126","id":"PMC_15162126","title":"Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells.","date":"2004","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/15162126","citation_count":35,"is_preprint":false},{"pmid":"38057426","id":"PMC_38057426","title":"Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy.","date":"2023","source":"Nature biomedical engineering","url":"https://pubmed.ncbi.nlm.nih.gov/38057426","citation_count":34,"is_preprint":false},{"pmid":"33739559","id":"PMC_33739559","title":"Beyond copy number: A new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients.","date":"2021","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/33739559","citation_count":34,"is_preprint":false},{"pmid":"19244360","id":"PMC_19244360","title":"Differential 3' splice site recognition of SMN1 and SMN2 transcripts by U2AF and U2 snRNP.","date":"2009","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19244360","citation_count":34,"is_preprint":false},{"pmid":"33060681","id":"PMC_33060681","title":"Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33060681","citation_count":34,"is_preprint":false},{"pmid":"21762474","id":"PMC_21762474","title":"Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III.","date":"2011","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21762474","citation_count":32,"is_preprint":false},{"pmid":"19287802","id":"PMC_19287802","title":"Phenotype modifiers of spinal muscular atrophy: the number of SMN2 gene copies, deletion in the NAIP gene and probably gender influence the course of the disease.","date":"2009","source":"Acta biochimica Polonica","url":"https://pubmed.ncbi.nlm.nih.gov/19287802","citation_count":32,"is_preprint":false},{"pmid":"25888055","id":"PMC_25888055","title":"Molecular characterization and copy number of SMN1, SMN2 and NAIP in Chinese patients with spinal muscular atrophy and unrelated healthy controls.","date":"2015","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/25888055","citation_count":31,"is_preprint":false},{"pmid":"21821450","id":"PMC_21821450","title":"Correlation of SMN2, NAIP, p44, H4F5 and Occludin genes copy number with spinal muscular atrophy phenotype in Tunisian patients.","date":"2011","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/21821450","citation_count":31,"is_preprint":false},{"pmid":"18533950","id":"PMC_18533950","title":"SMN2 and NAIP gene dosages in Vietnamese patients with spinal muscular atrophy.","date":"2008","source":"Pediatrics international : official journal of the Japan Pediatric Society","url":"https://pubmed.ncbi.nlm.nih.gov/18533950","citation_count":30,"is_preprint":false},{"pmid":"35316106","id":"PMC_35316106","title":"Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).","date":"2022","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/35316106","citation_count":30,"is_preprint":false},{"pmid":"26931466","id":"PMC_26931466","title":"Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26931466","citation_count":30,"is_preprint":false},{"pmid":"25645699","id":"PMC_25645699","title":"Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7.","date":"2015","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/25645699","citation_count":30,"is_preprint":false},{"pmid":"19330716","id":"PMC_19330716","title":"Splicing therapeutics in SMN2 and APOB.","date":"2009","source":"Current opinion in molecular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19330716","citation_count":29,"is_preprint":false},{"pmid":"18078930","id":"PMC_18078930","title":"Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy.","date":"2007","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18078930","citation_count":29,"is_preprint":false},{"pmid":"21561730","id":"PMC_21561730","title":"Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines.","date":"2011","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/21561730","citation_count":27,"is_preprint":false},{"pmid":"26438828","id":"PMC_26438828","title":"SAM68 is a physiological regulator of SMN2 splicing in spinal muscular atrophy.","date":"2015","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26438828","citation_count":26,"is_preprint":false},{"pmid":"18546169","id":"PMC_18546169","title":"Quantification of SMN1 and SMN2 genes by capillary electrophoresis for diagnosis of spinal muscular atrophy.","date":"2008","source":"Electrophoresis","url":"https://pubmed.ncbi.nlm.nih.gov/18546169","citation_count":26,"is_preprint":false},{"pmid":"24632473","id":"PMC_24632473","title":"PSF contacts exon 7 of SMN2 pre-mRNA to promote exon 7 inclusion.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24632473","citation_count":25,"is_preprint":false},{"pmid":"23390132","id":"PMC_23390132","title":"Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23390132","citation_count":24,"is_preprint":false},{"pmid":"16439605","id":"PMC_16439605","title":"Determination of SMN1/SMN2 gene dosage by a quantitative genotyping platform combining capillary electrophoresis and MALDI-TOF mass spectrometry.","date":"2006","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16439605","citation_count":24,"is_preprint":false},{"pmid":"22274580","id":"PMC_22274580","title":"Homozygous SMN2 deletion is a protective factor in the Swedish ALS population.","date":"2012","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/22274580","citation_count":24,"is_preprint":false},{"pmid":"22763238","id":"PMC_22763238","title":"Hypoxia is a modifier of SMN2 splicing and disease severity in a severe SMA mouse model.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22763238","citation_count":24,"is_preprint":false},{"pmid":"38772209","id":"PMC_38772209","title":"Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life.","date":"2024","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/38772209","citation_count":23,"is_preprint":false},{"pmid":"20705738","id":"PMC_20705738","title":"A humanized Smn gene containing the SMN2 nucleotide alteration in exon 7 mimics SMN2 splicing and the SMA disease phenotype.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20705738","citation_count":23,"is_preprint":false},{"pmid":"21705024","id":"PMC_21705024","title":"Identification of bidirectional gene conversion between SMN1 and SMN2 by simultaneous analysis of SMN dosage and hybrid genes in a Chinese population.","date":"2011","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21705024","citation_count":23,"is_preprint":false},{"pmid":"22233647","id":"PMC_22233647","title":"Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay.","date":"2012","source":"Journal of biomolecular screening","url":"https://pubmed.ncbi.nlm.nih.gov/22233647","citation_count":21,"is_preprint":false},{"pmid":"34620695","id":"PMC_34620695","title":"Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam.","date":"2021","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/34620695","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48837,"output_tokens":7030,"usd":0.12598,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16109,"output_tokens":6536,"usd":0.121972,"stage2_stop_reason":"end_turn"},"total_usd":0.247952,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"A single C-to-T transition at position +6 in exon 7 is the critical difference between SMN1 and SMN2; this change causes the majority of SMN2 transcripts to skip exon 7, producing a shorter isoform, by disrupting an exonic splice enhancer activity.\",\n      \"method\": \"Complete genomic sequencing and comparison of SMN1 and SMN2 clones; splicing assays demonstrating differential exon 7 inclusion\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct sequencing plus functional splicing assays in the same study; independently replicated across multiple subsequent labs\",\n      \"pmids\": [\"10369862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Htra2-beta1, an SR-like splicing factor, promotes inclusion of SMN exon 7 by binding an AG-rich exonic splicing enhancer in SMN2 exon 7, thereby restoring full-length SMN2 expression.\",\n      \"method\": \"In vivo splicing assays with Htra2-beta1 overexpression in human and mouse cells carrying an SMN2 minigene; RNA-binding assays demonstrating direct interaction with the ESE\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — overexpression and RNA-binding assays, replicated in multiple cell systems and confirmed by subsequent studies\",\n      \"pmids\": [\"10931943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SMN2 transgene expression in Smn-null mice rescues embryonic lethality; one or two transgene copies produce severe SMA-like motor neuron loss, while eight copies rescue the phenotype, demonstrating that phenotypic severity is modulated by the level of SMN produced from SMN2.\",\n      \"method\": \"Transgenic mouse generation; crossing onto Smn-/- background; histological and survival analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue experiment in vivo with dose-response, foundational animal model study widely replicated\",\n      \"pmids\": [\"10655541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The SMN1 and SMN2 gene promoters are nearly identical (~750 bp 5'-flanking region drives expression), with only a ~2-fold difference in reporter activity, ruling out promoter differences as the explanation for why SMN1 but not SMN2 is the disease-determining gene.\",\n      \"method\": \"Reporter construct transfection assays in motor neuron cell line using 750-bp 5'-flanking fragments from each gene\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct reporter assay with both promoters tested in parallel, single lab but multiple constructs\",\n      \"pmids\": [\"10366716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The C-to-T transition in SMN2 exon 7 creates an exonic splicing silencer (ESS) that functions as a binding site for hnRNP A1, which represses SMN2 exon 7 splicing; RNAi knockdown of hnRNP A1 in cells promotes efficient SMN2 exon 7 inclusion.\",\n      \"method\": \"Mutagenesis of exon 7; RNA-protein interaction assays; siRNA knockdown of hnRNP A1 in living cells with splicing readout\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis, RNA-protein binding, and functional RNAi in cells; confirmed by multiple independent laboratories\",\n      \"pmids\": [\"12833158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The C-to-T transition in SMN2 exon 7 results in loss of an SF2/ASF-dependent exonic splicing enhancer (ESE); hnRNP A/B proteins antagonize SF2/ASF-dependent ESE activity and promote exon 7 skipping independently of the C-to-T transition, representing a mechanism common to both SMN1 and SMN2.\",\n      \"method\": \"Mutagenesis, RNA interference, overexpression of splicing factors, RNA splicing assays, and RNA-protein interaction experiments\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (mutagenesis, RNAi, OE, binding assays) in a single study\",\n      \"pmids\": [\"16385450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"SMNDelta7 (the major SMN2 product lacking exon 7) associates with full-length SMN protein, and this association stabilizes SMNDelta7 and increases oligomeric SMN, ameliorating the SMA phenotype in transgenic mice.\",\n      \"method\": \"Transgenic mouse generation (SMNDelta7 crossed onto severe SMA background); survival analysis; co-immunoprecipitation/association assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic rescue plus molecular association assays; widely cited and built upon\",\n      \"pmids\": [\"15703193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"hnRNP A1 specifically binds SMN2 exon 7 (but not SMN1) and represses its splicing via the ESS mechanism; ASF/SF2 depletion does not affect SMN1/2 splicing, supporting the ESS-not-ESE model as primary mechanism.\",\n      \"method\": \"hnRNP A1 depletion by two independent methods; RNA-protein interaction assays; splicing assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent depletion methods plus binding assays, multiple orthogonal approaches\",\n      \"pmids\": [\"17884807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Two tandem hnRNP A1/A2 motifs in the intron 7 intronic splicing silencer (ISS-N1) repress SMN2 exon 7 inclusion; antisense oligonucleotides (ASOs) blocking these motifs promote very efficient exon 7 inclusion in transgenic mice in vivo.\",\n      \"method\": \"ASO tiling screen; mutagenesis; splicing assays; RNA-affinity chromatography; protein overexpression; in vivo ASO delivery in transgenic mice\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis, RNA-affinity chromatography, in vitro and in vivo validation with multiple orthogonal methods\",\n      \"pmids\": [\"18371932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Sam68 binds to the C-to-T transition-created binding site in SMN2 exon 7 (confirmed by RNA pull-down and UV-crosslink), triggers SMN2 exon 7 skipping, and dominant-negative Sam68 mutants that block hnRNP A1 recruitment enhance exon 7 inclusion and rescue SMN protein in SMA patient fibroblasts.\",\n      \"method\": \"RNA pull-down; UV crosslink; in vivo splicing assays; mutagenesis of Sam68 RNA-binding domain; retroviral dominant-negative mutant expression\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — RNA-protein binding, mutagenesis, and functional rescue in patient cells, multiple orthogonal methods\",\n      \"pmids\": [\"20186123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"hnRNP Q isoforms differentially regulate SMN2 exon 7 splicing: the major isoform Q1 directly binds SMN exon 7 near position +6 and promotes exon 7 inclusion, while minor isoforms Q2/Q3 antagonize Q1 and induce exon 7 exclusion.\",\n      \"method\": \"Affinity chromatography; overexpression and knockdown of hnRNP Q isoforms; splicing assays in HeLa cells and testis of SMN2 transgenic mice\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — affinity chromatography plus functional assays in cells and tissue, single lab\",\n      \"pmids\": [\"18794368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The C-to-T transition in SMN2 exon 7 reduces U2AF65 crosslinking and U2 snRNP association at the 3' splice site of intron 6 compared to SMN1, suggesting that differential U2 snRNP recruitment is a control point in SMN2 exon 7 splicing regulation.\",\n      \"method\": \"UV crosslinking of U2AF65; native gel electrophoresis of U2 snRNP assembly on SMN1 vs SMN2 RNAs; competition assays in HeLa nuclear extract\",\n      \"journal\": \"RNA (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution with nuclear extract, multiple assays, single lab\",\n      \"pmids\": [\"19244360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SMN protein abundance positively feeds back on SMN2 exon 7 splicing: reduced SMN protein lowers cellular snRNA levels, which in turn decreases SMN2 exon 7 inclusion, creating a self-amplifying feedback loop that exacerbates SMN deficiency.\",\n      \"method\": \"SMN depletion in cells; measurement of snRNA levels; SMN2 splicing assays; manipulation of individual snRNP levels with functional readout\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell-based experiments with depletion and snRNP manipulation, single lab\",\n      \"pmids\": [\"20884664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Selective SMN depletion in motor neuronal progenitors (but not abolition) is sufficient to cause an SMA-like phenotype with neuromuscular junction defects, motor neuron degeneration, and muscle atrophy in model mice expressing human SMN2, establishing a cell-autonomous role for SMN in motor neurons.\",\n      \"method\": \"Conditional SMN knockdown in motor neuronal progenitors using Cre-mediated approach in SMN2-expressing mice; electrophysiology; histology; NMJ analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic knockdown with multiple phenotypic readouts including electrophysiology and histology\",\n      \"pmids\": [\"20826664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Intracerebroventricular delivery of a 2'-MOE ASO targeting the ISS-N1 element in SMN2 intron 7 produces robust, long-lasting SMN2 exon 7 inclusion in spinal cord motor neurons at both mRNA and protein levels, and a single neonatal injection rescues tail and ear necrosis in SMA mice.\",\n      \"method\": \"Micro-osmotic pump ICV infusion; quantitative RT-PCR and immunoblot of spinal cord; neonatal ICV injection in SMA mice with phenotype rescue readout\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct CNS delivery with mRNA, protein, and functional phenotype rescue readouts, multiple experimental arms\",\n      \"pmids\": [\"20624852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SMN(A111G), an allele competent for snRNP assembly, rescues SMA mice only when combined with SMN from SMN2, indicating that SMN(A111G) and SMN2-derived SMN undergo intragenic complementation in heteromeric complexes with higher snRNP assembly activity; correction of SMA correlates directly with snRNP assembly activity in spinal cord.\",\n      \"method\": \"Transgenic rescue experiments; snRNP assembly assays; snRNA level measurement in spinal cord of rescued vs unrescued mice\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis combined with biochemical snRNP assembly assays, multiple animal genotypes\",\n      \"pmids\": [\"19329542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SAM68 binds SMN2 pre-mRNA and favors recruitment of the splicing repressor hnRNP A1 while interfering with U2AF65 binding at the 3' splice site of exon 7; genetic knockout of SAM68 promotes SMN2 exon 7 inclusion in SMA mice and partially rescues body weight, viability, and motor neuron/muscle defects.\",\n      \"method\": \"SAM68 knockout in SMA mouse model; SMN2 splicing assay; molecular mechanism by RNA-binding and spliceosome factor recruitment analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in disease model with mechanistic analysis of splicing factor recruitment, multiple phenotypic readouts\",\n      \"pmids\": [\"26438828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"hnRNP G binds to an SMN2 exon 7-derived RNA via its RRM domain interacting with a 5'-AAN-3' motif (specifically recognizing two consecutive adenines), and is recruited to a polyA tract upstream of the Tra2-beta1 binding site; this interaction, together with the RGG box, is required for hnRNP G to activate exon 7 inclusion as part of a Tra2-beta1/hnRNP G/SRSF9 trimeric complex.\",\n      \"method\": \"NMR structure of hnRNP G RRM bound to SMN2-derived RNA; mutagenesis of RRM and binding sites; splicing assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure with mutagenesis validation and functional splicing assays in same study\",\n      \"pmids\": [\"24692659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"hnRNP M binds an enhancer on SMN2 exon 7 (overlapping the Tra2-beta1 binding site) and promotes exon 7 inclusion by recruiting U2AF65 to the flanking intron; knockdown promotes exon 7 skipping and overexpression promotes inclusion in SMA patient cells.\",\n      \"method\": \"Knockdown and overexpression of hnRNP M; RNA-binding assays; U2AF65 recruitment assay; splicing assays in SMA patient cells\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA binding plus functional splicing assays with KD and OE, single lab\",\n      \"pmids\": [\"24533984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PSF (polypyrimidine tract-binding protein-associated splicing factor) binds the GAAGGA enhancer in SMN2 exon 7 and promotes exon 7 inclusion; mutation of this enhancer abolishes PSF's effect; PSF and Tra2-beta1 target partially overlapping sequences in exon 7.\",\n      \"method\": \"Overexpression and knockdown of PSF; mutagenesis of GAAGGA enhancer; RNA-protein interaction assays; splicing assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA binding, mutagenesis, KD and OE, single lab\",\n      \"pmids\": [\"24632473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Small-molecule SMN2 splicing modifiers stabilize the transient double-stranded RNA structure formed between the SMN2 pre-mRNA 5' splice site and U1 snRNP, increasing U1 snRNP binding affinity in a sequence-selective manner distinct from constitutive splicing recognition.\",\n      \"method\": \"Biochemical U1 snRNP binding assays; RNA structural analysis; in vitro and in vivo splicing assays; survival studies in severe SMA mouse model\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mechanistic biochemical reconstitution of U1 snRNP binding plus structural RNA analysis and in vivo rescue, multiple orthogonal methods\",\n      \"pmids\": [\"26030728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The A-44G transition in SMN2 intron 6 improves exon 7 splicing by markedly decreasing binding of the RNA-binding protein HuR (which acts as a splicing repressor at the -44 region); identified by RNA-affinity chromatography and mass spectrometry combined with systematic mutagenesis.\",\n      \"method\": \"Minigene systematic mutagenesis; RNA-affinity chromatography; mass spectrometry identification of HuR; functional splicing assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — RNA affinity chromatography/MS identification plus mutagenesis and functional splicing validation\",\n      \"pmids\": [\"28460014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SMN2 splicing modifier small molecules (risdiplam class) directly bind to two distinct sites on the SMN2 pre-mRNA, stabilizing a ribonucleoprotein (RNP) complex that confers gene selectivity, rather than targeting the general splicing machinery.\",\n      \"method\": \"RNA splicing assays; transcription assays; protein chemistry; combination of RNA and protein binding techniques demonstrating direct pre-mRNA binding\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding to pre-mRNA shown by multiple biochemical/chemical methods, single lab but orthogonal approaches\",\n      \"pmids\": [\"29133793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SMN-C2 and SMN-C3 (risdiplam analogs) directly bind the AGGAAG motif on SMN2 exon 7 pre-mRNA and promote a conformational change in unpaired nucleotides at the intron 6/exon 7 junction, creating a new binding surface that recruits FUBP1 and KHSRP to enhance SMN2 splicing.\",\n      \"method\": \"Chemical proteomics; SHAPE/structure probing of SMN2 pre-mRNA in vitro and in-cell; identification of recruited splicing factors FUBP1 and KHSRP\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct RNA binding mapping, RNA structural probing, and factor recruitment identification with multiple orthogonal methods\",\n      \"pmids\": [\"29712837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The stem-loop RNA structure TSL2 (overlapping the 5' splice site of SMN2 exon 7) is a drugable target; the small molecule PK4C9 binds pentaloop conformations of TSL2 and promotes a shift to triloop conformations that enhance exon 7 splicing, rescuing downstream molecular alterations in SMA cells.\",\n      \"method\": \"High-resolution NMR with molecular modelling of PK4C9-TSL2 complex; SMN2 splicing assays; SMA cell molecular rescue readouts\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure of small molecule-RNA complex combined with functional splicing rescue\",\n      \"pmids\": [\"29795225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Valproic acid increases full-length SMN2 mRNA and protein 2- to 4-fold in SMA patient fibroblasts, likely through elevation of Htra2-beta1 (which facilitates SMN2 exon 7 correct splicing) as well as through SMN gene transcription activation.\",\n      \"method\": \"Treatment of SMA patient fibroblast cultures with VPA; quantitative RT-PCR of SMN2 transcripts; western blot; immunofluorescence of gems; VPA treatment of rat hippocampal brain slices\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based and organotypic experiments with mRNA and protein readouts, single lab\",\n      \"pmids\": [\"12915451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Hypoxia increases hnRNP A1 and Sam68 levels in cells and promotes SMN2 exon 7 skipping; this hypoxia-induced skipping requires the SMN2 C>T mutation and is mediated through hnRNP A1 binding sites; hyperoxia treatment in SMA mice increases SMN2 exon 7 inclusion in skeletal muscle and improves motor function.\",\n      \"method\": \"Cell culture hypoxia treatment; SMN2 minigene splicing assays; mutation of hnRNP A1 binding sites; hyperoxia treatment in SMA mice with motor function readout\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — minigene mutagenesis, cell-based and in vivo experiments, single lab\",\n      \"pmids\": [\"22763238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZPR1 binds RNA polymerase II, interacts with the SMN locus in vivo, and upregulates SMN2 expression; ZPR1 overexpression in SMA mice increases systemic SMN levels, rescues motor function, and reduces neurodegeneration; ZPR1 also elevates senataxin levels, reduces R-loop accumulation, and rescues DNA damage in SMA.\",\n      \"method\": \"ZPR1-RNA Pol II binding assay; chromatin immunoprecipitation at SMN locus; ZPR1 overexpression in SMA mice; SMN level quantification; R-loop and DNA damage assays in patient cells and mice\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple molecular and in vivo assays, single lab\",\n      \"pmids\": [\"31828288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Exon-specific U1 snRNAs (ExSpe U1s) complementary to intronic sequences downstream of the SMN2 exon 7 5' splice site promote exon 7 inclusion and stabilize the SMN pre-mRNA intermediate, resulting in higher SMN mRNA levels than antisense oligonucleotides targeting the same intronic region; AAV-delivered ExSpe U1 increases exon 7 inclusion in multiple tissues of SMN2 transgenic mice.\",\n      \"method\": \"Integrated ExSpe U1 expression; pre-mRNA stability assay; comparison with ASO; AAV delivery in SMN2 transgenic mice with tissue-level splicing analysis\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cellular models plus in vivo AAV delivery, single lab\",\n      \"pmids\": [\"25557785\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SMN2 produces predominantly exon-7-skipped, unstable SMNDelta7 protein due to a single C-to-T transition at exon 7 position +6, which simultaneously destroys an SF2/ASF-dependent exonic splicing enhancer and creates an hnRNP A1-binding exonic splicing silencer; additional repression is exerted by hnRNP A1/A2 motifs in the intron 7 ISS-N1 element, by Sam68 (which recruits hnRNP A1 and blocks U2AF65), by HuR binding at intron 6 position -44, and by hypoxia-induced upregulation of hnRNP A1 and Sam68, while positive regulators including Htra2-beta1/SRSF10, hnRNP G, hnRNP M, PSF, hnRNP Q1, and ZPR1 act on exon 7 enhancers or at the transcriptional level to increase full-length SMN2 output; small-molecule splicing modifiers (risdiplam, branaplam class) directly bind specific RNA structures in the SMN2 pre-mRNA (AGGAAG motif on exon 7 and/or TSL2 stem-loop at the 5' splice site) to stabilize U1 snRNP recognition and recruit additional splicing activators (FUBP1, KHSRP), thereby shifting splicing toward full-length SMN protein, and SMN2 copy number inversely correlates with SMA severity because more copies produce cumulatively more full-length SMN protein, which itself feeds back to maintain snRNP levels required for efficient exon 7 splicing.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SMN2 is a near-identical paralog of SMN1 whose disease relevance in spinal muscular atrophy derives from a single C-to-T transition at exon 7 position +6 that causes most transcripts to skip exon 7 and produce an unstable, truncated SMNDelta7 isoform, while a minority of transcripts retain exon 7 to yield functional full-length SMN [#0]. The transition acts at the RNA level rather than through the essentially identical promoters [#3]: it simultaneously abolishes an SF2/ASF-dependent exonic splicing enhancer [#5] and creates an exonic splicing silencer that recruits the repressor hnRNP A1, whose depletion restores exon 7 inclusion [#4, #7]. Additional repression operates through tandem hnRNP A1/A2 motifs in the intron 7 ISS-N1 element [#8], through Sam68/SAM68, which recruits hnRNP A1 and blocks U2AF65 at the exon 7 3' splice site [#9, #16], and through HuR binding near intron 6 position -44 [#21], with reduced U2AF65 and U2 snRNP recruitment a key downstream consequence of the transition [#11]. Opposing these silencers, Htra2-beta1, hnRNP G and hnRNP M act on exon 7 enhancers to drive inclusion [#1, #17, #18], while transcriptional activators such as ZPR1 raise overall SMN2 output [#27]. SMN2 copy number determines SMA severity because cumulative full-length SMN restores snRNP assembly, and SMN itself feeds back on snRNA levels to maintain efficient exon 7 splicing [#2, #12, #15]; SMN function in motor neurons is cell-autonomous [#13]. These mechanisms define the therapeutic strategy of redirecting SMN2 splicing toward full-length protein, achieved by ISS-N1-targeting antisense oligonucleotides [#8, #14] and by small-molecule modifiers that bind defined RNA elements (the exon 7 AGGAAG motif and the 5' splice-site TSL2 stem-loop) to stabilize U1 snRNP recognition and recruit activators such as FUBP1 and KHSRP [#20, #23, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established why SMN1 and SMN2 differ functionally despite sequence identity, pinpointing a single exon 7 nucleotide change as the cause of exon 7 skipping.\",\n      \"evidence\": \"Complete genomic sequencing and splicing assays comparing SMN1/SMN2 clones\",\n      \"pmids\": [\"10369862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The molecular identity of the disrupted enhancer/silencer factor was not resolved\", \"Did not establish whether the effect was enhancer loss or silencer gain\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Ruled out promoter/transcriptional differences as the explanation for SMN1-versus-SMN2 disease determination, focusing attention on post-transcriptional splicing.\",\n      \"evidence\": \"Parallel reporter assays of 750-bp 5'-flanking fragments in a motor neuron line\",\n      \"pmids\": [\"10366716\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reporter context may not capture native chromatin regulation\", \"Modest 2-fold difference not functionally tested in vivo\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated that SMN dosage from SMN2 directly sets phenotypic severity in vivo, validating SMN2 as the disease-modifying gene and copy-number determinant.\",\n      \"evidence\": \"SMN2 transgene copy-number titration on a Smn-null mouse background with survival/histology\",\n      \"pmids\": [\"10655541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the splicing mechanism limiting full-length output\", \"Mouse SMN2 expression may differ from human tissue distribution\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified the first positive trans-acting regulator, showing exon 7 inclusion can be enhanced by an SR-like factor binding an exonic enhancer.\",\n      \"evidence\": \"Htra2-beta1 overexpression with SMN2 minigenes and RNA-binding assays\",\n      \"pmids\": [\"10931943\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether endogenous Htra2-beta1 is rate-limiting in motor neurons\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Provided early pharmacological proof that small molecules can raise full-length SMN2 output, linking it to Htra2-beta1 and transcriptional activation.\",\n      \"evidence\": \"Valproic acid treatment of SMA fibroblasts and rat brain slices with mRNA/protein readouts\",\n      \"pmids\": [\"12915451\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism inferred, not directly demonstrated as causal\", \"Magnitude of effect modest (2-4 fold)\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved the molecular consequence of the C-to-T change as creation of a silencer, identifying hnRNP A1 as the responsible repressor.\",\n      \"evidence\": \"Exon 7 mutagenesis, RNA-protein binding, and hnRNP A1 RNAi in cells\",\n      \"pmids\": [\"12833158\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not reconcile with concurrent enhancer-loss models\", \"Did not address intronic repressor contributions\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined a parallel enhancer-loss mechanism (SF2/ASF-dependent ESE) and an hnRNP A/B antagonism common to both genes, broadening the regulatory model.\",\n      \"evidence\": \"Mutagenesis, RNAi, overexpression, and RNA-protein binding assays\",\n      \"pmids\": [\"16385450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative weight of ESE-loss versus ESS-gain left unsettled\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Explained why residual SMNDelta7 is not entirely inert, showing it associates with and is stabilized by full-length SMN to partially ameliorate disease.\",\n      \"evidence\": \"SMNDelta7 transgenic crosses with survival and association assays\",\n      \"pmids\": [\"15703193\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of stabilized SMNDelta7 to function not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Reinforced the silencer-centric model by showing hnRNP A1 binds SMN2 but not SMN1 exon 7 and that ASF/SF2 depletion does not alter splicing.\",\n      \"evidence\": \"Two independent hnRNP A1 depletion methods plus binding and splicing assays\",\n      \"pmids\": [\"17884807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Apparent conflict with ESE-loss model not fully reconciled\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified the intron 7 ISS-N1 element and its tandem hnRNP A1/A2 motifs as a potent silencer, defining the highest-value antisense therapeutic target.\",\n      \"evidence\": \"ASO tiling, mutagenesis, RNA-affinity chromatography, and in vivo ASO delivery in mice\",\n      \"pmids\": [\"18371932\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term and clinical efficacy not addressed in this study\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Implicated Sam68 as a repressor acting at the C-to-T site and showed dominant-negative Sam68 rescues SMN in patient cells.\",\n      \"evidence\": \"RNA pull-down, UV-crosslink, mutagenesis, and dominant-negative expression\",\n      \"pmids\": [\"20186123\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance not yet tested at this stage\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Added isoform-specific complexity by showing hnRNP Q1 promotes while Q2/Q3 antagonize exon 7 inclusion.\",\n      \"evidence\": \"Affinity chromatography, overexpression/knockdown, splicing assays in cells and mouse tissue\",\n      \"pmids\": [\"18794368\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; physiological isoform balance in motor neurons unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Provided biochemical evidence that the C-to-T change weakens U2AF65 crosslinking and U2 snRNP recruitment, linking the silencer to early spliceosome assembly.\",\n      \"evidence\": \"UV crosslinking and native-gel U2 snRNP assembly in HeLa nuclear extract\",\n      \"pmids\": [\"19244360\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro extract may not reflect motor neuron context\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed that correction of SMA correlates directly with snRNP assembly activity and that SMN2-derived SMN complements via heteromeric complexes.\",\n      \"evidence\": \"Transgenic rescue with snRNP assembly and snRNA assays in spinal cord\",\n      \"pmids\": [\"19329542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether snRNP assembly fully accounts for motor neuron pathology unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established a self-amplifying feedback loop in which low SMN reduces snRNA and further suppresses exon 7 inclusion, worsening deficiency.\",\n      \"evidence\": \"SMN depletion, snRNA measurement, and snRNP manipulation with splicing readout\",\n      \"pmids\": [\"20884664\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; quantitative contribution of the loop to disease progression unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated a cell-autonomous requirement for SMN in motor neurons, defining the relevant cellular target of SMN2-derived protein.\",\n      \"evidence\": \"Conditional SMN knockdown in motor neuronal progenitors with electrophysiology and NMJ analysis\",\n      \"pmids\": [\"20826664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Non-cell-autonomous contributions not excluded\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Provided CNS proof-of-concept that ISS-N1 ASO delivery restores SMN in spinal motor neurons and rescues phenotype.\",\n      \"evidence\": \"ICV 2'-MOE ASO infusion and neonatal injection in SMA mice with mRNA/protein/phenotype readouts\",\n      \"pmids\": [\"20624852\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Durability and systemic distribution not fully characterized here\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped the structural basis and trimeric complex (Tra2-beta1/hnRNP G/SRSF9) by which hnRNP G activates exon 7 inclusion.\",\n      \"evidence\": \"NMR structure of hnRNP G RRM bound to SMN2 RNA with mutagenesis and splicing assays\",\n      \"pmids\": [\"24692659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo therapeutic relevance not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified hnRNP M as an enhancer-binding activator that recruits U2AF65 to promote exon 7 inclusion.\",\n      \"evidence\": \"Knockdown/overexpression, RNA-binding, and U2AF65 recruitment assays in patient cells\",\n      \"pmids\": [\"24533984\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; in vivo role unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified PSF as a GAAGGA-enhancer-binding activator overlapping the Tra2-beta1 target.\",\n      \"evidence\": \"Overexpression/knockdown, enhancer mutagenesis, and RNA-binding assays\",\n      \"pmids\": [\"24632473\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; physiological contribution unquantified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Confirmed Sam68's in vivo significance by showing genetic knockout enhances exon 7 inclusion and partially rescues SMA mice through impaired hnRNP A1 recruitment and U2AF65 displacement.\",\n      \"evidence\": \"SAM68 knockout in SMA mice with mechanistic splicing factor recruitment analysis\",\n      \"pmids\": [\"26438828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Only partial rescue; off-target Sam68 functions not dissected\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated an alternative RNA-based therapeutic using exon-specific U1 snRNAs that outperform ASOs by stabilizing pre-mRNA intermediates.\",\n      \"evidence\": \"ExSpe U1 expression, pre-mRNA stability assays, and AAV delivery in SMN2 transgenic mice\",\n      \"pmids\": [\"25557785\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; clinical translatability not addressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed the core mechanism of small-molecule splicing modifiers: stabilizing the transient pre-mRNA/U1 snRNP duplex at the 5' splice site in a sequence-selective manner.\",\n      \"evidence\": \"Biochemical U1 snRNP binding, RNA structural analysis, and in vivo SMA mouse survival\",\n      \"pmids\": [\"26030728\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of recruited factors not yet defined at this stage\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified HuR as an intron 6 (-44) repressor whose displacement by the A-44G change improves splicing.\",\n      \"evidence\": \"Minigene mutagenesis, RNA-affinity chromatography/MS, and splicing assays\",\n      \"pmids\": [\"28460014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HuR can be therapeutically modulated not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed risdiplam-class modifiers act by directly binding two distinct pre-mRNA sites and stabilizing a selective RNP rather than the general spliceosome.\",\n      \"evidence\": \"RNA/transcription/protein binding assays demonstrating direct pre-mRNA binding\",\n      \"pmids\": [\"29133793\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of all recruited factors not fully enumerated here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the molecular details of modifier action, mapping binding to the exon 7 AGGAAG motif and identifying FUBP1 and KHSRP as recruited activators.\",\n      \"evidence\": \"Chemical proteomics, in vitro/in-cell SHAPE probing, and factor identification\",\n      \"pmids\": [\"29712837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of FUBP1 versus KHSRP not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established the TSL2 stem-loop at the 5' splice site as a druggable RNA conformational switch for enhancing exon 7 splicing.\",\n      \"evidence\": \"NMR/modelling of PK4C9-TSL2 complex with splicing rescue in SMA cells\",\n      \"pmids\": [\"29795225\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy of this chemotype not demonstrated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked environmental hypoxia to splicing repression via induction of hnRNP A1 and Sam68, with hyperoxia improving SMN2 inclusion in vivo.\",\n      \"evidence\": \"Cell hypoxia, minigene mutagenesis of hnRNP A1 sites, and hyperoxia treatment in SMA mice\",\n      \"pmids\": [\"22763238\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; clinical relevance of oxygenation uncertain\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified ZPR1 as a transcriptional/genome-stability regulator that raises SMN2 expression, rescues motor function, and reduces R-loop-associated DNA damage.\",\n      \"evidence\": \"RNA Pol II binding, ChIP at SMN locus, ZPR1 overexpression in SMA mice, and R-loop/DNA damage assays\",\n      \"pmids\": [\"31828288\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; therapeutic feasibility of ZPR1 modulation untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many overlapping enhancer/silencer factors are integrated and prioritized in human motor neurons, and which are rate-limiting therapeutic targets, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative hierarchy of trans-acting regulators in motor neurons unknown\", \"Combinatorial logic linking splicing factor occupancy to exon 7 outcome undefined\", \"Long-term durability of splice-redirecting therapies not established in this corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [4, 8, 9, 17, 21, 23]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 4, 8, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 27]}\n    ],\n    \"complexes\": [\"snRNP\"],\n    \"partners\": [\"SMN1\", \"hnRNP A1\", \"Sam68\", \"Htra2-beta1\", \"hnRNP G\", \"U2AF65\", \"FUBP1\", \"KHSRP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}